Quarry LP increased its stake in agilon health, inc. (NYSE:AGL – Free Report) by 500.3% during the second quarter, according to its most recent filing with the SEC. The fund owned 18,254 shares of the company’s stock after buying an additional 15,213 shares during the quarter. Quarry LP’s holdings in agilon health were worth $119,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AGL. Bank of Nova Scotia bought a new stake in shares of agilon health during the fourth quarter valued at about $305,000. Capital International Investors boosted its stake in agilon health by 16.2% in the fourth quarter. Capital International Investors now owns 10,934,636 shares of the company’s stock worth $137,230,000 after buying an additional 1,521,995 shares in the last quarter. Capital World Investors boosted its stake in agilon health by 7.4% in the fourth quarter. Capital World Investors now owns 55,218,496 shares of the company’s stock worth $692,992,000 after buying an additional 3,813,214 shares in the last quarter. Caas Capital Management LP purchased a new stake in agilon health in the fourth quarter worth approximately $151,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in agilon health by 46.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,139,886 shares of the company’s stock worth $127,256,000 after buying an additional 3,195,087 shares in the last quarter.
agilon health Price Performance
Shares of NYSE AGL opened at $3.67 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.36 and a quick ratio of 1.36. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -5.24 and a beta of 0.54. The firm’s 50 day simple moving average is $4.71 and its 200-day simple moving average is $5.43. agilon health, inc. has a 12 month low of $3.07 and a 12 month high of $20.37.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft dropped their price objective on agilon health from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, August 9th. Benchmark reiterated a “buy” rating and issued a $9.00 price objective on shares of agilon health in a report on Thursday, August 8th. Evercore ISI increased their price objective on agilon health from $5.50 to $7.00 and gave the stock an “in-line” rating in a report on Tuesday, July 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of agilon health in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.57.
View Our Latest Research Report on AGL
Insiders Place Their Bets
In other news, CEO Steven Sell bought 20,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average price of $3.36 per share, for a total transaction of $67,200.00. Following the completion of the transaction, the chief executive officer now owns 67,590 shares of the company’s stock, valued at $227,102.40. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.20% of the stock is owned by company insiders.
agilon health Company Profile
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Recommended Stories
- Five stocks we like better than agilon health
- 3 Fintech Stocks With Good 2021 Prospects
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 5 Top Rated Dividend Stocks to Consider
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Breakout Stocks: What They Are and How to Identify Them
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding AGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for agilon health, inc. (NYSE:AGL – Free Report).
Receive News & Ratings for agilon health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for agilon health and related companies with MarketBeat.com's FREE daily email newsletter.